DK1056452T3 - Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter - Google Patents

Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter

Info

Publication number: DK1056452T3
Authority: DK; Denmark
Prior art keywords: indole; propionic acid; ester; salt; effective amount
Prior art date: 1998-02-23

Application number

DK99908381T

Other languages

English (en)

Inventor

Jorge Ghiso

Burkhard Poeggeler

Miguel A Pappolla

Blas Frangione

Original Assignee

Univ South Alabama

Univ New York

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-23

Filing date

1999-02-23

Publication date

2006-11-20

1999-02-23 Application filed by Univ South Alabama, Univ New York filed Critical Univ South Alabama

2006-11-20 Application granted granted Critical

2006-11-20 Publication of DK1056452T3 publication Critical patent/DK1056452T3/da

Links

GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 title abstract 10
150000002148 esters Chemical class 0.000 title abstract 5
239000003290 indole 3-propionic acid Substances 0.000 title abstract 5
150000003839 salts Chemical class 0.000 title abstract 5
239000003814 drug Substances 0.000 title 1
239000012472 biological sample Substances 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
230000035557 fibrillogenesis Effects 0.000 abstract 1
230000002600 fibrillogenic effect Effects 0.000 abstract 1
230000003647 oxidation Effects 0.000 abstract 1
238000007254 oxidation reaction Methods 0.000 abstract 1
230000036542 oxidative stress Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)

DK99908381T 1998-02-23 1999-02-23 Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter DK1056452T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7555598P	1998-02-23	1998-02-23
US11256598P	1998-12-16	1998-12-16

Publications (1)

Publication Number	Publication Date
DK1056452T3 true DK1056452T3 (da)	2006-11-20

Family

ID=26757006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99908381T DK1056452T3 (da)	1998-02-23	1999-02-23	Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter

Country Status (17)

Country	Link
US (1)	US6395768B1 (da)
EP (1)	EP1056452B1 (da)
JP (2)	JP5627160B2 (da)
CN (1)	CN1147299C (da)
AT (1)	ATE333275T1 (da)
AU (1)	AU757925B2 (da)
BR (1)	BR9908165A (da)
CA (1)	CA2321455C (da)
DE (1)	DE69932414T2 (da)
DK (1)	DK1056452T3 (da)
EA (1)	EA005244B1 (da)
ES (1)	ES2270585T3 (da)
IL (2)	IL137848A0 (da)
MX (1)	MXPA00008216A (da)
NZ (1)	NZ506260A (da)
PT (1)	PT1056452E (da)
WO (1)	WO1999042102A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6322802B1 (en)	1999-06-01	2001-11-27	The Regents Of The University Of California	Method of sterilizing
US6719988B2 (en)	1997-02-21	2004-04-13	The Regents Of The University Of California	Antiseptic compositions for inactivating prions
US6720355B2 (en)	1997-02-21	2004-04-13	The Regents Of The University Of California	Sodium dodecyl sulfate compositions for inactivating prions
US6419916B1 (en)	1999-06-01	2002-07-16	The Regents Of The University Of California	Assay for compounds which affect conformationally altered proteins
DE10006139A1 (de) *	2000-02-11	2001-08-16	Merck Patent Gmbh	Indol-3-yl-Derivate
US7491699B2 (en)	2002-12-09	2009-02-17	Ramot At Tel Aviv University Ltd.	Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (en)	2003-01-07	2004-07-22	Ramot At Tel Aviv University Ltd.	Peptide nanostructures encapsulating a foreign material and method of manufacturing same
BRPI0412684A (pt) *	2003-07-17	2006-10-03	Plexxinko Inc	compostos ppar-ativos
US7348338B2 (en) *	2003-07-17	2008-03-25	Plexxikon, Inc.	PPAR active compounds
US7125861B2 (en) *	2003-07-31	2006-10-24	Rolland F Hebert	Water-soluble chitosan-indole-3-propionic acid conjugates
EP1663199B1 (en)	2003-09-25	2013-04-03	Tel Aviv University Future Technology Development L.P.	Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en)	2003-10-02	2005-04-07	Ramot At Tel Aviv University Ltd.	Novel antibacterial agents and methods of identifying and utilizing same
WO2005062851A2 (en) *	2003-12-22	2005-07-14	Pappolla Miguel A	Indole-3-propionamide and derivatives thereof
WO2006013552A2 (en)	2004-08-02	2006-02-09	Ramot At Tel Aviv University Ltd.	Articles of peptide nanostructures and method of forming the same
EP1793816B1 (en)	2004-08-19	2012-01-04	Tel Aviv University Future Technology Development L.P.	Compositions for treating amyloid associated diseases
AU2005311826A1 (en) *	2004-11-30	2006-06-08	Plexxikon, Inc.	Indole derivatives for use as PPAR active compounds
EP1819673A2 (en) *	2004-11-30	2007-08-22	Plexxikon, Inc.	Indole derivatives for use as ppar active compounds
JP2008545663A (ja) *	2005-05-27	2008-12-18	クイーンズユニバーシティアットキングストン	タンパク質フォールディング障害の治療
CA2621406A1 (en) *	2005-09-07	2007-03-15	Plexxikon, Inc.	Pparactive compounds
CA2621275A1 (en) *	2005-09-07	2007-03-15	Plexxikon, Inc.	1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
US10004828B2 (en)	2005-10-11	2018-06-26	Romat at Tel-Aviv University Ltd.	Self-assembled Fmoc-ff hydrogels
EP2061459B1 (en) *	2006-08-23	2012-12-26	Intellect Neurosciences Inc.	3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
PE20090159A1 (es) *	2007-03-08	2009-02-21	Plexxikon Inc	COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US9744155B2 (en)	2012-03-28	2017-08-29	Ixcela, Inc.	IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
CN105934520A (zh) *	2014-01-31	2016-09-07	伊克斯塞拉有限公司	作为生物标志物的共价键代谢物
CN108125950B (zh) *	2017-12-28	2020-09-25	崔明	吲哚丙酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途
JP2020083827A (ja) *	2018-11-27	2020-06-04	国立研究開発法人農業・食品産業技術総合研究機構	ケミカルシャペロンまたは神経細胞死の抑制剤
US11041847B1 (en)	2019-01-25	2021-06-22	Ixcela, Inc.	Detection and modification of gut microbial population
CN109674787A (zh) *	2019-02-01	2019-04-26	百迈康生物医药科技(广州)有限公司	一种防治缺血性心脏病的药物及其应用
CN109730993A (zh) *	2019-02-28	2019-05-10	北京大学人民医院(北京大学第二临床医学院)	吲哚丙酸在制备防治类风湿关节炎药物中的应用
WO2020185913A1 (en) *	2019-03-12	2020-09-17	Intellect Neurosciences, Inc.	Indole-3-propionic acids and salts and esters thereof for treating skin disorders
EP4076424A1 (en) *	2019-12-20	2022-10-26	Basf Se	Composition for the treatment of amyloid-beta associated diseases
CN118141804A (zh) *	2024-03-06	2024-06-07	浙江大学	吲哚-3-丙酸在制备用于增敏肿瘤免疫治疗的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4536505A (en) *	1983-05-17	1985-08-20	Ciba-Geigy Corporation	Certain N-(pyridyl) indoles
JP2602735B2 (ja) *	1989-09-27	1997-04-23	株式会社大塚製薬工場	抗活性酸素剤
JPH0578248A (ja) *	1991-03-04	1993-03-30	Mitsubishi Gas Chem Co Inc	活性酸素消去剤
JPH0578247A (ja) *	1991-03-04	1993-03-30	Mitsubishi Gas Chem Co Inc	活性酸素消去剤
WO1993010087A1 (en) *	1991-11-18	1993-05-27	G.D. Searle & Co.	Derivatives of cyclic phenolic thioethers as inhibitors or stimulators of superoxide generation
EP0654024A1 (en) *	1992-08-06	1995-05-24	Warner-Lambert Company	2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
IT1265101B1 (it) *	1993-07-23	1996-10-30	Erba Carlo Spa	Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
JPH0881442A (ja) *	1994-07-14	1996-03-26	Otsuka Pharmaceut Co Ltd	環状アミド誘導体
MX9700696A (es) *	1994-07-27	1997-04-30	Sankyo Co	Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
JPH08175993A (ja) *	1994-12-21	1996-07-09	Green Cross Corp:The	抗酸化剤
JPH09249567A (ja) *	1996-01-12	1997-09-22	Otsuka Pharmaceut Co Ltd	医薬組成物
TW430660B (en) *	1996-05-30	2001-04-21	Mochida Pharm Co Ltd	Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them

1999
- 1999-02-23 DE DE69932414T patent/DE69932414T2/de not_active Expired - Lifetime
- 1999-02-23 BR BR9908165-2A patent/BR9908165A/pt not_active Application Discontinuation
- 1999-02-23 CN CNB998032441A patent/CN1147299C/zh not_active Expired - Fee Related
- 1999-02-23 NZ NZ506260A patent/NZ506260A/en not_active IP Right Cessation
- 1999-02-23 EA EA200000874A patent/EA005244B1/ru not_active IP Right Cessation
- 1999-02-23 EP EP99908381A patent/EP1056452B1/en not_active Expired - Lifetime
- 1999-02-23 WO PCT/US1999/003906 patent/WO1999042102A1/en not_active Ceased
- 1999-02-23 IL IL13784899A patent/IL137848A0/xx unknown
- 1999-02-23 ES ES99908381T patent/ES2270585T3/es not_active Expired - Lifetime
- 1999-02-23 AT AT99908381T patent/ATE333275T1/de active
- 1999-02-23 PT PT99908381T patent/PT1056452E/pt unknown
- 1999-02-23 MX MXPA00008216A patent/MXPA00008216A/es active IP Right Grant
- 1999-02-23 CA CA2321455A patent/CA2321455C/en not_active Expired - Lifetime
- 1999-02-23 AU AU27828/99A patent/AU757925B2/en not_active Ceased
- 1999-02-23 DK DK99908381T patent/DK1056452T3/da active
- 1999-02-23 JP JP2000532118A patent/JP5627160B2/ja not_active Expired - Fee Related
2000
- 2000-05-30 US US09/580,437 patent/US6395768B1/en not_active Expired - Lifetime
- 2000-08-14 IL IL137848A patent/IL137848A/en not_active IP Right Cessation
2011
- 2011-10-20 JP JP2011230632A patent/JP2012017343A/ja active Pending

Also Published As

Publication number	Publication date
CN1147299C (zh)	2004-04-28
US6395768B1 (en)	2002-05-28
JP2002503691A (ja)	2002-02-05
CN1292693A (zh)	2001-04-25
CA2321455A1 (en)	1999-08-26
EP1056452B1 (en)	2006-07-19
EA200000874A1 (ru)	2001-02-26
MXPA00008216A (es)	2004-11-22
DE69932414D1 (de)	2006-08-31
WO1999042102A8 (en)	2001-02-15
ES2270585T3 (es)	2007-04-01
BR9908165A (pt)	2000-10-31
EA005244B1 (ru)	2004-12-30
ATE333275T1 (de)	2006-08-15
NZ506260A (en)	2003-05-30
JP2012017343A (ja)	2012-01-26
JP5627160B2 (ja)	2014-11-19
IL137848A (en)	2010-11-30
WO1999042102A1 (en)	1999-08-26
IL137848A0 (en)	2001-10-31
CA2321455C (en)	2010-10-19
EP1056452A1 (en)	2000-12-06
DE69932414T2 (de)	2007-02-22
HK1036588A1 (en)	2002-01-11
AU757925B2 (en)	2003-03-13
AU2782899A (en)	1999-09-06
PT1056452E (pt)	2006-12-29

Publication	Publication Date	Title
IL137848A0 (en)	2001-10-31	Indole-3-propionic acids, salts and esters thereof used as medicaments
ES2056854T3 (es)	1994-10-16	Tiadiazinonas.
ATE442851T1 (de)	2009-10-15	1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
ATE262900T1 (de)	2004-04-15	Therapeutische und lebensmittel-zusammensetzungen,welche essentielle fettsäuren und bioaktive disulfide enthalten
NO904378D0 (no)	1990-10-10	Fremgangsmaate for fremstilling av et modifisert protein for terapeutisk anvendelse.
IT1176916B (it)	1987-08-18	Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
DE69027865D1 (de)	1996-08-22	ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DE3778699D1 (de)	1992-06-04	Verwendung von vitamin e zur herstellung von arzneimitteln zur normalisierung der blutgerinnung bei therapie mit hochungesaettigten fettsaeuren vom omega-3-typ.
DK1227820T3 (da)	2006-08-21	Oligosaccharidaldonsyrer og topisk anvendelse deraf
DE69004081D1 (de)	1993-11-25	Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
DE69624768D1 (de)	2002-12-19	Ernährungszusammensetzung
ES2192839T3 (es)	2003-10-16	Timosina beta 4 oxidada.
ES2196027T3 (es)	2003-12-16	Tratamiento de enfermedades vasculares degenerativas mediante modulacion de la produccion o actividad del oxido nitrico exogeno.
NO914217D0 (no)	1991-10-28	Sakkarinderivater nyttige som proteolytiske enzyminhibitorer og fremstilling derav
NO166939C (no)	1991-09-18	Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
DE69725882D1 (de)	2003-12-04	Adenovirus e4 proteine für induktion von zelltod
ATE126061T1 (de)	1995-08-15	Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
SE8801710D0 (sv)	1988-05-05	New ophtalmological composition of matter
ES2038216T3 (es)	1993-07-16	Procedimiento para la preparacion de 5-(3-alquil-5-t-butil-4-hidroxi-fenil)-2-amino-6h-1,3,4-tiadazinas y su empleo.
ES2044170T3 (es)	1994-01-01	Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
ATE5256T1 (de)	1983-11-15	Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
FI891210A7 (fi)	1989-03-14	Tiosulfiinihappojohdannaiset, niiden käyttö tulehdussairauksien käsitt elyyn sekä näitä aineita sisältävät lääkeaineet
DE69807672D1 (de)	2002-10-10	Von milchsäure abgeleitete butyrat-prodrugs
ATE79265T1 (de)	1992-08-15	Mittel zur behandlung mykotischer, mikrobischer und anderer gewebsschaedigender und pathologischer manifestationen und gewebsdeformationen.
ATE2746T1 (de)	1983-03-15	Piperidinderivate von 4,5-dialkyl-3-hydroxypyrrol-2-carbons[ureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.